BioAtla, LLC Announces the Appointment of Scott Smith, as President
September 10, 2018 at 03:30 pm IST
Share
BioAtla, LLC announced the appointment of Scott Smith, as President. Mr. Smith, an experienced biotechnology and pharmaceutical executive, joins the Company from Celgene Corporation, where he was President and Chief Operating Officer.
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Companyâs product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.